Table of Contents:
Quote of the day
Memory Air
Interesting stories this week
Three Major Drug Developments Shaping Alzheimer’s Treatment
Responding to YOU!
Caregiving is a series of small acts of care that alter the course of someone’s life.
Memory Air – the all-in-one olfactory enrichment device.
Memory Air brings this science backed olfactory enrichment approach to your house in an easy-to-use device that works while you sleep.
Developed in partnership with Professor Emeritus of Neurobiology at the University of California Irvine, Dr Michael Leon is one of the world’s leading neuroscientists.
Memory Air was designed using proven science:
226% memory improvements in adults aged 60-85
300% memory improvements in people living with Alzheimer’s / other dementias
Only available in the USA
Interesting Stories This Week:
Football and dementia support
Sleep and brain health: a final reminder
Walking together for a future without Alzheimer’s
The nut neurologists recommend for brain health
How much exercise does the brain really need?
Three Major Drug Developments Shaping Alzheimer’s Treatment
Over the past few years, Alzheimer’s research has reached a significant turning point. Treatments targeting amyloid plaques have moved from theory into clinical use, marking an important shift for the field.
Drugs such as Kisunla (donanemab) and Leqembi (lecanemab), developed by Eli Lilly and Eisai in collaboration with Biogen, received approval in 2023 and 2024. These approvals validated the amyloid hypothesis, which suggests that amyloid plaque build up plays a role in the progression of Alzheimer’s disease.
However, amyloid targeted therapies are not the full answer. There remains a clear need for treatments that work through different biological mechanisms and offer alternative formats beyond regular infusions.
Three developments currently stand out.
Lilly’s next generation amyloid therapy
Following the approval of Kisunla, Eli Lilly is developing a second amyloid targeting drug called remternetug. In Phase 2 trials, remternetug demonstrated rapid and robust clearance of amyloid plaques.
The ongoing Phase 3 trial is enrolling 1,574 patients and is expected to complete in March this year. If successful, this could strengthen Lilly’s position while further refining amyloid based treatment approaches.
Amovio Bio’s oral alternative
Amovio Bio is taking a different approach with buntanetap tartrate, a once daily oral drug currently in Phase 2 trials. Unlike existing infusion based treatments, buntanetap is taken as a tablet and works through a non amyloid mechanism.
The planned Phase 3 trial will include 760 participants who will receive the drug daily, with evaluations at six months and eighteen months. This study is expected to run until December 2027.
Ari Bio’s AR-1001
Ari Bio is also progressing its treatment AR-1001 through Phase 3 trials. In Phase 2 studies, the 30 mg once daily oral dose showed significant improvement, marking it as another promising non infusion option.
Why this matters
Together, these developments highlight a broader shift in Alzheimer’s research. While amyloid targeting drugs have opened the door, future progress is likely to depend on diversified treatment options that vary in mechanism, delivery, and suitability for different patients.
For families and caregivers, these trials represent cautious progress rather than immediate answers, but they point towards a future with more choice and more personalised care.
A Problem Shared is a Problem Halved
Every week, we share an honest story from a caregiver — the things most people are too afraid to say out loud.
This Week’s Caregiver Story-
One of the things I worry about most is whether my husband is eating enough.
He has very little appetite and often says he is not hungry, even when he has barely eaten all day. I find myself watching what he eats, encouraging small meals, and feeling anxious when food is left untouched.
I know I cannot force him, but it is hard not to worry when eating feels so tied to health, strength, and energy. Some days it feels like another quiet responsibility I am carrying on my own.
Harvey says:
Thank you for sharing this. Loss of appetite is a common and distressing challenge for many carers, particularly when food feels like one of the few things you can still actively help with.
It is important to recognise that reduced appetite is often linked to changes in the brain, medication side effects, fatigue, or altered sensory perception. In many cases, it is not a matter of choice or stubbornness, even though it can feel that way in daily life.
What you are describing is a form of constant vigilance. Watching, encouraging, worrying, and weighing up when to step in and when to step back. That ongoing attention takes emotional energy, even when nothing visibly happens.
Focusing on smaller, more frequent meals and prioritising foods that are easier to eat or particularly nourishing can sometimes help. Equally important is being gentle with yourself. You are doing your best in a situation where there are no perfect answers.
Your concern comes from care, not control. And you are not alone in carrying this worry.
Harvey
If something’s been on your heart lately, let us know. We read every word. Your voice could offer comfort to someone else navigating the same journey.
At All About Alzheimer's we're dementia professionals but we're not medical doctors or lawyers. The information we provide is for general informational purposes only and should not be considered as medical or legal advice. Always consult with a qualified healthcare professional for medical diagnoses, treatment or any health related concerns and consult with a lawyer on any legal issue.
There's an affiliate link which means we may earn a commission if you click and make a purchase at no additional cost to you.
We only recommend products and services we trust.